RG7388: Selective MDM2 Antagonist for p53 Pathway Activation

2026-01-20

RG7388 is a highly potent MDM2 antagonist that selectively activates the p53 pathway, leading to cancer cell apoptosis in wild-type p53 models. As a second-generation clinical inhibitor, RG7388 demonstrates superior potency over earlier compounds and shows efficacy in preclinical tumor models. This article details its mechanistic basis, benchmarks, and workflow parameters for translational oncology.